Hemostemix Inc. (CVE:HEM – Get Free Report) was down 14.5% on Tuesday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares changed hands during trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Trading Down 14.5 %
The firm’s fifty day moving average price is C$0.11 and its 200-day moving average price is C$0.08. The company has a market cap of C$23.09 million, a price-to-earnings ratio of -13.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Stock Market Sectors: What Are They and How Many Are There?
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Are Penny Stocks a Good Fit for Your Portfolio?
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
- Profitably Trade Stocks at 52-Week Highs
- Gold’s Momentum Persists: Leading ETF and 2 Stocks to Watch
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
